What the business is, and whether it's a good one at a fair price.
A pharmaceuticals company operating in India and the local pharma arm of Abbott Laboratories. It is a pharma-only firm (no medical devices or diagnostics in its Indian operations) that reported Rs 6,929 crore in revenue from operations for FY26, up 8.1% from FY25. Manufacturing is concentrated at a single formulation plant in Goa, supported by 3,467 permanent employees. Recent launches included Extensior (semaglutide) for Type 2 diabetes and Ezybixy for chronic constipation, extending its branded pharma portfolio. Operating costs are spread across materials at 8.9% of revenue, employee costs at 9.7% and other operating expenses at 9.7%, with depreciation at 1.1%. EBITDA for FY26 was Rs 2,180 crore, translating to a 31.46% EBITDA margin, and profit after tax stood at Rs 1,552 crore.
Measured from the filed financials, judged against its Pharmaceuticals peers · as of FY26 — not investment advice
How has the market priced it — with filings on the timeline?
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
How does it stack up on valuation, returns and growth?
Loading peers…
Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.
Loading financials…
Who owns it — and is the promoter stake clean?
Loading shareholding…
Sign up to see the full company file
Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.
Answered from ABBOTT INDIA LIMITED's filed financials and exchange disclosures
ABBOTT INDIA LIMITED is a Pharmaceuticals & Biotechnology company listed on NSE and BSE, trading under the symbol ABBOTINDIA.
Yes. Over the trailing twelve months ABBOTT INDIA LIMITED reported a net profit of ₹1,552 Cr on revenue of ₹6,929 Cr.
Yes. The dividend yield is 1.86% at the current price. It paid out 65% of its profit as dividend in FY26.
Effectively yes. It holds ₹442 Cr more cash than debt. Debt stands at 0.00× equity.
On trailing P/E, ABBOTT INDIA LIMITED ranks 97 of 169 in Pharmaceuticals — cheaper than 43% of them, against an industry median of 28.9×. This is a position, not a valuation judgement.
On a typical session ABBOTT INDIA LIMITED moves 0.69% — that is the median absolute close-to-close move across its last 269 trading days. Announcement days are routinely larger.
Every NSE and BSE filing by ABBOTT INDIA LIMITED appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.
Figures are as last reported and may lag the latest filing. Not investment advice.
